Clinical trials offer early access to cutting-edge treatments that can lead to progress in research, improved treatment options, and better outcomes. Through clinical trials, researchers can better understand how to diagnose, treat, and prevent diseases or conditions, which brings us one step closer to a world without autoimmune disease.
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), or Systemic Sclerosis (SSc)
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases.
Lupus Nephritis
The PALIZADE clinical trial will evaluate zetomipzomib as a potential new treatment for adults living with lupus nephritis. Kezar Life Sciences is conducting this trial to assess zetomipzomib for the treatment of lupus nephritis, its side effects, and how it affects proteins in the urine. Zetomipzomib is a first-in-class, investigational product being studied for the treatment of autoimmune diseases, including lupus nephritis, a serious complication of systemic lupus erythematosus. Zetomipzomib acts by inhibiting the immunoproteasome, a structure found in immune cells that helps to regulate the normal functioning of the immune system.
Autoimmune Hepatitis (AIH)
PORTOLA is a randomized, double-blind, placebo-controlled phase 2a study with an open-label extension to evaluate the safety and efficacy of zetomipzomib (KZR-616) in people living with autoimmune hepatitis (AIH). Zetomipzomib is a first-in-class, investigational product being studied for the treatment of autoimmune diseases, including autoimmune hepatitis, a rare and chronic autoimmune liver disease. Zetomipzomib acts by inhibiting the immunoproteasome, a structure found in immune cells that helps to regulate the normal functioning of the immune system.
Browse current studies with filters that allow you to search by condition, treatment, location, and more.
